Fernando Bril

The University of Alabama

United States

Research Interests

Explore related searches

Professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (26)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (9)

Rickey Carter

Professor, Biostatistics

Mayo Clinic

UNITED STATES

View details

Fabrizia Carli

ITALY

View details

Yonghui Wu

Assistant Professor

University of Florida

UNITED STATES

View details

Reginald Frye

Professor and Chair

University of Florida College of Pharmacy

UNITED STATES

View details

Diana Barb

Associate Professor

University of Florida

UNITED STATES

View details

Melanie Giselle Cree

Associate Professor, Director Multi-disciplinary PCOS clinic, Director 31P MR Spectroscopy Core

University of Colorado Health

UNITED STATES

View details

Norbert Stefan

GERMANY

View details

Ricardo Azziz

The University of Alabama

UNITED STATES

View details

Zhulin He

Emory University

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Fernando Bril

Research Interests

Explore related searches

Contact this professor

Articles (26)

Approach to the Patient: Hirsutism

Role of Hepatic Glycogen on Nocturnal Gluconeogenesis in Type 2 Diabetes Mellitus

Will a “multivitamin” a day keep the “MASLD doctor” away?

Prevalence of MASLD in People With Diabetes Has Decreased in the US, but Rates of Liver Fibrosis Are Still on the Rise

Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease

Response to Letter to the Editor From de Zegher and Ibáñez: “Adipose Tissue Dysfunction in Polycystic Ovary Syndrome”

The Association Between Obesity and Polycystic Ovary Syndrome: An Epidemiologic Study of Observational Data

Economic Burden of Endometrial Cancer Associated With Polycystic Ovary Syndrome

Metabolic characteristics of patients with MetALD: Caveats of a new definition

Insulin resistance is an integral feature of MASLD even in the presence of PNPLA3 variants

Researchers call for more flexible editorial conduct rather than abruptly adopting only the new MASLD nomenclature

Noninvasive tests to identify liver fibrosis in metabolic dysfunction‐associated steatotic liver disease are affected by race

Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

Fasting intact insulin by mass spectrometry is associated with metabolic dysfunction–associated steatotic liver disease in youth

Adipose Tissue Insulin Resistance Predicts the Severity of Liver Fibrosis in Patients With Type 2 Diabetes and NAFLD

Pioglitazone discontinuation in patients with nonalcoholic steatohepatitis is associated with disease recurrence

Hypercholesterolemia After COVID-19: Time to Include Lipoprotein X Among the Differential Diagnoses

Noninvasive Diagnosis of Nonalcoholic Steatohepatitis and Advanced Liver Fibrosis Using Machine Learning Methods: Comparative Study With Existing Quantitative Risk Scores

Differences in HDL-Bound Apolipoproteins in Patients With Advanced Liver Fibrosis Due to Nonalcoholic Fatty Liver Disease

PPAR‐γ‐induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH

Autoimmunity after Coronavirus Disease 2019 (COVID-19) Vaccine: A Case of Acquired Hemophilia A

Intact Fasting Insulin Identifies Nonalcoholic Fatty Liver Disease in Patients Without Diabetes

Reply to: “Comment on “Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) vaccine: Causality or casualty?””

What the New Definition of Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Left Behind: Genetically Acquired Fatty Liver Disease (GAFLD)

Collaborators (9)

Rickey Carter

Fabrizia Carli

Yonghui Wu

Reginald Frye

Diana Barb

Melanie Giselle Cree

Norbert Stefan

Ricardo Azziz

Zhulin He

Make your next move.